Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD3 | Q99594 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12092298 | 0.83 | CHRM2 (0.35) | TSHRTDP1SMN1; SMN2 | |
| SCHEMBL12080288 | 0.83 | MEN1 (0.42) | TSHRTDP1PKMSMN1; SMN2ALDH1A1 | |
| SCHEMBL12092155 | 0.82 | CHRM2 (0.36) | TSHRTDP1SMN1; SMN2 | |
| SCHEMBL12092154 | 0.81 | MEN1 (0.40) | TSHRTDP1PKMSMN1; SMN2ALDH1A1 | |
| SCHEMBL25242998 | 0.81 | HRH2 (0.40) | TSHRALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL931672 | 0.77 | NPSR1 (0.41) | TSHRTDP1PKMSMN1; SMN2ALDH1A1 | |
| SCHEMBL3430112 | 0.76 | TSHR (0.55) | TSHRTDP1PKMSMN1; SMN2ALDH1A1 | |
| SCHEMBL12092216 | 0.75 | TSHR (0.47) | TSHRTDP1PKMSMN1; SMN2ALDH1A1 | |
| SCHEMBL12092182 | 0.75 | TSHR (0.47) | TSHRTDP1PKMSMN1; SMN2ALDH1A1 | |
| SCHEMBL15435923 | 0.74 | NAMPT (0.43) | TDP1SMN1; SMN2ALDH1A1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952147-B2 | Conjugates, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2015-02-10 | — | — | US | disclosed |
| US-20120225089-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-09-06 | — | — | US | disclosed |
| EP-2448929-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011001052-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011001052-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225089-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | ERG28, CARS1, FOLH1 | TEAD3 3856/4885TSHR 4077/4885TDP1 3206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.